New molecules modulating bone metabolism - new perspectives in the treatment of osteoporosis
Language English Country Czech Republic Media print
Document type Journal Article, Review
PubMed
28948818
DOI
10.33549/physiolres.933720
PII: 933720
Knihovny.cz E-resources
- MeSH
- Diphosphonates administration & dosage MeSH
- Bone Density drug effects physiology MeSH
- Humans MeSH
- Antibodies, Monoclonal administration & dosage MeSH
- Osteogenesis drug effects physiology MeSH
- Osteoporosis drug therapy metabolism MeSH
- Bone Remodeling drug effects physiology MeSH
- Vitamin D administration & dosage MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Diphosphonates MeSH
- Antibodies, Monoclonal MeSH
- Vitamin D MeSH
In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, as well as a drug with an anabolic effect on the skeleton, parathormone. However, there is also a focus on non-traditional strategies used in therapy for osteolytic diseases. The newest antiosteoporotic pharmaceuticals increase osteoblast differentiation via BMP signaling (harmine), or stimulate osteogenic differentiation of mesenchymal stem cells through Wnt/beta-catenin (icarrin, isoflavonoid caviunin, or sulfasalazine). A certain promise in the treatment of osteoporosis is shown by molecules targeting non-coding microRNAs (which are critical for osteoclastogenesis) or those stimulating osteoblast activity via epigenetic mechanisms. Vitamin D metabolites have specific antiosteoporotic potencies, modulating the skeleton not only via mineralization, but markedly also through the direct effects on the bone microstructure.
References provided by Crossref.org
Expression of osteogenic factors in FasL-deficient calvarial cells
The effects of titanium topography and chemical composition on human osteoblast cell
